Confirming the findings of the activation screen, overexpression of either canonical (CTNNβ1) or non-canonical (FZD6) genes of the Wnt pathway confers resistance to TMZ treatment in glioblastoma cells (Figure 4A,B). This evidence concerns the gene FZD6 and glioblastoma.